advertisement
Li Q 19
Showing records 1 to 19 | Display all abstracts from Li Q128609 OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line
Wen D
IBRO neuroscience reports 2025; 19: 307-316
128579 Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives
Liu F
Stem cell reviews and reports 2025; 21: 2386-2406
127624 Early diagnosis of primary open-angle glaucoma using isolated-check visual evoked potential with blue-on-yellow perimetry
Li Q
BMC Ophthalmology 2025; 25: 483
127672 Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety
Li Q
Journal of Medicinal Chemistry 2025; 68: 10008-10030
128579 Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives
Li Q
Stem cell reviews and reports 2025; 21: 2386-2406
127624 Early diagnosis of primary open-angle glaucoma using isolated-check visual evoked potential with blue-on-yellow perimetry
Liu D
BMC Ophthalmology 2025; 25: 483
127672 Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety
Li C
Journal of Medicinal Chemistry 2025; 68: 10008-10030
128609 OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line
Li Q
IBRO neuroscience reports 2025; 19: 307-316
127624 Early diagnosis of primary open-angle glaucoma using isolated-check visual evoked potential with blue-on-yellow perimetry
Zhang M
BMC Ophthalmology 2025; 25: 483
127672 Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety
Chang Y
Journal of Medicinal Chemistry 2025; 68: 10008-10030
128609 OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line
Li Y
IBRO neuroscience reports 2025; 19: 307-316
128579 Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives
Yang Y
Stem cell reviews and reports 2025; 21: 2386-2406
128609 OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line
Yan W
IBRO neuroscience reports 2025; 19: 307-316
128579 Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives
Lu F
Stem cell reviews and reports 2025; 21: 2386-2406
127672 Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety
Su M; Yu R
Journal of Medicinal Chemistry 2025; 68: 10008-10030
128609 OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line
Wang Y
IBRO neuroscience reports 2025; 19: 307-316
127672 Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety
Huang Z
Journal of Medicinal Chemistry 2025; 68: 10008-10030
128609 OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line
Liu Y
IBRO neuroscience reports 2025; 19: 307-316
127672 Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety
Guo YW; Jin X
Journal of Medicinal Chemistry 2025; 68: 10008-10030
